Press release
Natural Killer Cell Therapies Pipeline Analysis 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Ph
Natural Killer Cell Therapies Pipeline Analysis
DelveInsight reports that the Natural Killer (NK) Cell Therapies pipeline involves over 100 key companies actively developing more than 140 therapeutic candidates.
Natural Killer Cell Therapies Overview:
Natural killer (NK) cells are a type of lymphocyte that play a vital role in the innate immune system. These specialized immune cells are key defenders against tumors and virus-infected cells. In cancer patients, NK cells often exhibit abnormalities, including reduced cytotoxic activity, impaired expression of activating receptors or signaling proteins, increased levels of inhibitory receptors, limited proliferation, decreased presence in the bloodstream and tumor tissues, and disrupted cytokine production.
NK cell-based therapies have demonstrated particular promise in treating blood cancers like leukemia. Approaches to NK immunotherapy generally involve either activating the patient's own NK cells using specific stimulators or introducing externally sourced NK cells via methods such as hematopoietic stem cell transplantation (HSCT) or adoptive cell transfer. Numerous strategies have now been developed to leverage NK cells in cancer treatment.
Download our report @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Natural Killer Cell Therapies Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Natural Killer Cell Therapies Therapeutics Market.
Key Takeaways from the Natural Killer Cell Therapies Pipeline Report
DelveInsight's report on the Natural Killer (NK) Cell Therapies pipeline highlights a dynamic landscape, with over 100 companies actively developing more than 140 therapeutic candidates.
Key regulatory updates include:
*
June 2024: GT Biopharma received FDA clearance for its IND application for GTB-3650, an NK cell engager targeting CD33+ leukemia, with Phase 1 trials anticipated in the second half of 2024.
*
April 2024: The FDA approved ANKTIVA (an IL-15 receptor agonist) for BCG-unresponsive non-muscle invasive bladder cancer, which works by activating the body's NK and T cells to target tumor cells.
*
April 2024: NKGen Biotech obtained FDA IND clearance to begin a Phase 1/2a trial of SNK01, an autologous NK cell therapy for Parkinson's disease.
Leading companies advancing NK cell therapies include ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (formerly Cell Medica), and others.
Promising NK cell therapy candidates in development include Monalizumab, NKTR-214 (Bempegaldesleukin), ALT-803, ALECSAT, PNK-007, among several others.
Natural Killer Cell Therapies Pipeline Analysis
The Natural Killer Cell Therapies pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Natural Killer Cell Therapies Market.
*
Categorizes Natural Killer Cell Therapies therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Natural Killer Cell Therapies drugs under development based on:
*
Stage of development
*
Natural Killer Cell Therapies Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Natural Killer Cell Therapies Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Natural Killer Cell Therapies Licensing agreements
*
Funding and investment activities supporting future Natural Killer Cell Therapies market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Natural Killer Cell Therapies Emerging Drugs
*
Monalizumab: Innate Pharma
*
NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
*
ALT 803: ImmunityBio
*
ALECSAT: CytoVac
*
PNK-007: Celularity
Natural Killer Cell Therapies Companies
More than 100 leading companies are actively developing Natural Killer (NK) Cell Therapies, with Innate Pharma advancing a drug candidate to the most advanced stage-Phase III clinical trials.
DelveInsight's report covers around 140+ products under different phases of Natural Killer Cell Therapies clinical trials like
*
Natural Killer Cell Therapies Late stage Therapies (Phase III)
*
Natural Killer Cell Therapies Mid-stage Therapies (Phase II)
*
Natural Killer Cell Therapies Early-stage Therapies (Phase I)
*
Natural Killer Cell Therapies Pre-clinical and Natural Killer Cell Therapies Discovery stage Therapies
*
Natural Killer Cell Therapies Discontinued & Inactive Therapies
Natural Killer Cell Therapies pipeline report provides the Natural Killer Cell Therapies therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Natural Killer Cell Therapies Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Natural Killer Cell Therapies Therapies and Key Natural Killer Cell Therapies Companies: Natural Killer Cell Therapies Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Natural Killer Cell Therapies Pipeline Therapeutic Assessment
- Natural Killer Cell Therapies Assessment by Product Type
- Natural Killer Cell Therapies By Stage
- Natural Killer Cell Therapies Assessment by Route of Administration
- Natural Killer Cell Therapies Assessment by Molecule Type
Download Natural Killer Cell Therapies Sample report to know in detail about the Natural Killer Cell Therapies treatment market @ Natural Killer Cell Therapies Therapeutic Assessment [https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Natural Killer Cell Therapies Current Treatment Patterns
4. Natural Killer Cell Therapies - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Natural Killer Cell Therapies Late-Stage Products (Phase-III)
7. Natural Killer Cell Therapies Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Natural Killer Cell Therapies Discontinued Products
13. Natural Killer Cell Therapies Product Profiles
14. Natural Killer Cell Therapies Key Companies
15. Natural Killer Cell Therapies Key Products
16. Dormant and Discontinued Products
17. Natural Killer Cell Therapies Unmet Needs
18. Natural Killer Cell Therapies Future Perspectives
19. Natural Killer Cell Therapies Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Natural Killer Cell Therapies Pipeline Reports Offerings [https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=natural-killer-cell-therapies-pipeline-analysis-2025-by-delveinsight-immunitybio-five-prime-therapeutics-innate-pharma-nektar-therapeutics-cantargia-curetech-dynavax-cellid-company-kiadis-ph]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Natural Killer Cell Therapies Pipeline Analysis 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Ph here
News-ID: 4165684 • Views: …
More Releases from ABNewswire
DUB Inhibitors Market to Surpass Multi-Billion-Dollar Milestone by 2040 Across 7 …
DUB Inhibitors Companies are InSilico Medicine, Molecure, KSQ Therapeutics, Roche, Mission Therapeutics, Cothera Bioscience, Asieris Pharmaceuticals, Tango Therapeutics, and others.
The DUB inhibitors market is set to witness consistent expansion, fueled by increasing focus on targeted protein degradation and the advancement of innovative oncology therapies. The rising burden of cancer and neurodegenerative conditions is further contributing to market growth. Moreover, the introduction of pipeline candidates such as ISM-3091 by InSilico Medicine,…
Ablation Devices Market to Reach USD 15,347.69 Million by 2032, Growing at 8.38% …
Global Ablation Devices Market Forecast 2025-2032 Highlights Strong Growth Momentum Across Oncology, Cardiology, and Pain Management Applications
The global Ablation Devices Market is poised for robust expansion, with market size projected to increase from USD 8,090.31 million in 2024 to USD 15,347.69 million by 2032, registering a strong CAGR of 8.38% during the forecast period (2025-2032). The steady growth trajectory reflects rising global demand for minimally invasive treatment modalities, technological innovation…
Balloon Valvuloplasty Device Market to Grow at 5.13% CAGR Through 2032, Driven b …
Balloon valvuloplasty device manufacturers include BD, PFM Medical ag, NuMED, Balton, TORAY INDUSTRIES, INC., Translumina, InterValve Medical, Inc., OSYPKA AG, SURETECH MEDICAL INC., simeks, and others.
The global Balloon Valvuloplasty Device Market is poised for steady expansion, projected to grow at a Compound Annual Growth Rate (CAGR) of 5.13% during the forecast period 2025-2032. Increasing prevalence of cardiovascular diseases (CVDs), rising adoption of minimally invasive cardiac procedures, technological advancements in interventional…
Insulin Resistance Pipeline Expands as 20+ Pharma Companies Progress Novel Thera …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies, including Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Genfit, Novartis, and others, developing 20+ pipeline drugs in the Insulin Resistance pipeline landscape.
DelveInsight's "Insulin Resistance - Pipeline Insight, 2026" report provides comprehensive insights…
More Releases for Therapies
Treg Cell-Based Therapies Clinical Trial Landscape Expands With 55+ Emerging The …
The "Treg Cell-Based Therapies Pipeline Insight" report delivers a detailed assessment of therapeutic programs spanning the entire development continuum, from early discovery and preclinical research to advanced clinical-stage candidates. It features comprehensive drug profiles highlighting mechanisms of action, clinical trial progress, regulatory milestones, and partnerships, funding activities, and enabling technology platforms influencing product development.
DelveInsight's most recent evaluation underscores the accelerated global momentum in the Treg Cell-Based Therapies domain, with over…
GM1 Gangliosidosis Market: Epidemiology, Therapies, Companies, DelveInsight | Pa …
GM1 Gangliosidosis therapies, such as PBGM01, and others, are expected to boost the GM1 Gangliosidosis Market in the upcoming years.
DelveInsight has launched a new report on "GM1 Gangliosidosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the GM1 Gangliosidosis, historical and forecasted epidemiology as well as the GM1 Gangliosidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover…
Intratumoral Cancer Therapies Market Report 2024 - Intratumoral Cancer Therapies …
"The Business Research Company recently released a comprehensive report on the Global Intratumoral Cancer Therapies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The intratumoral cancer therapies…
Innovative Therapies in Alcohol Rehabilitation
Alcohol rehabilitation has evolved significantly over the years, with innovative therapies emerging as crucial elements in the journey to recovery. These groundbreaking approaches go beyond traditional methods, providing individuals struggling with alcohol addiction with a diverse set of tools to achieve and maintain sobriety. In this article, we delve into innovative therapies, exploring their effectiveness and impact on alcohol rehabilitation if you'd like to know more about alcohol rehab in…
B-cell Maturation Antigen (BCMA) Targeted Therapies Market New Development of No …
A global prevalence of over one million cases. B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen targeted therapy for the treatment of multiple myeloma. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies,…
Viral Vector Contract Manufacturing Market Outlook 2021- Gene Therapies, Cell Th …
The latest report released on Outlook for Viral Vector Contract Manufacturing - Gene Therapies, Cell Therapies, and COVID-19 Vaccines Market analyses areas where there is still room for improvement. Irrespective of industry, organization size or geographic location, the Outlook for Viral Vector Contract Manufacturing - Gene Therapies, Cell Therapies, and COVID-19 Vaccines Market study suggests that advanced technologies are playing a bigger role than ever before. The assessment provides trend,…
